|Day Low/High||37.38 / 38.61|
|52 Wk Low/High||28.00 / 59.88|
PDUFA goal date extended by standard extension period of three months to June 30, 2017
Investors in Radius Health Inc saw new options become available this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RDUS options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Cramer says P&G is a good choice and is disappointed by Bristol-Myers Squibb.
A malaise has once again befallen America, Cramer says.
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
Cramer is avoiding TPC Composites and is lukewarm on Kinder Morgan.
Consistency and discipline are two values this market has sorely lacked in 2016, Cramer says.
Cramers is avoiding Nike and loves Newell so much he bought the company for Action Alerts PLUS.
The stocks we thought would be the strongest in 2016 are now losing their footing, Cramer says.
Results show consistency of Abaloparatide-SC responses across a wide range of patient subgroups
The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 739,137 share increase in total short interest for Radius Health Inc , to 7,245,291, an increase of 11.36% since 08/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Here's a technical look at how to trade five stocks within range of triggering big breakouts.
SABCS to include three abstracts from the development program for RAD1901 as a potential treatment of ER-positive advanced breast cancer
Results from Phase 3 ACTIVE trial show abaloparatide significantly reduced the incidence of new vertebral fractures and nonvertebral fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo
Board members who sit on four or more boards may find it impossible to manage their time when faced with an insurgent investor or merger situation -- or both.
The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.